NCT05865886View on ClinicalTrials.gov

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions
Cystic FibrosisBronchiectasis
Interventions
DRUG

BI 1291583

BI 1291583

DRUG

Placebo to BI 1291583

Placebo matching BI 1291583

Trial Locations (12)

3000

UZ Leuven, Leuven

10028

Northwell Health Physician Partners, New York

13353

Charite Universitätsmedizin Berlin KöR, Berlin

30625

Medizinische Hochschule Hannover, Hanover

37126

Azienda Ospedaliera Universitaria Integrata Verona, Verona

45239

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen

50139

Azienda Ospedaliera Meyer, Florence

66160

University of Kansas Medical Center, Kansas City

07747

Universitätsklinikum Jena, Jena

1081 HV

Amsterdam UMC, location VUMC, Amsterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05865886 - A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) | Biotech Hunter | Biotech Hunter